Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) can damage the gastrointestinal tract, causing widespread morbidity and mortality. Although mechanisms of damage involve the activities of prostaglandin-endoperoxide synthase 1 (PTGS1 or cyclooxygenase [COX] 1) and PTGS1 (COX2), other factors are involved. We review the mechanisms of gastrointestinal damage induction by NSAIDs via COX-mediated and COX-independent processes. NSAIDs interact with phospholipids and uncouple mitochondrial oxidative phosphorylation, which initiates biochemical changes that impair function of the gastrointestinal barrier. The resulting increase in intestinal permeability leads to low-grade inflammation. NSAID inhibition of COX enzymes, along with luminal aggressors, results in erosions and ulcers, with potential complications of bleeding, protein loss, stricture formation, and perforation. We propose a model for NSAID-induced damage to the gastrointestinal tract that includes these complex, interacting, and inter-dependent factors. This model highlights the obstacles for the development of safer NSAIDs.

Pilot Study Indicates Helicobacter pylori Infection May Induce Small Intestinal Mucosal Injury

“…Hence, small intestinal mucosal injury is not infrequent with the treatment. The etiology of NSAIDs-induced small intestinal mucosal injury is relatively solved [7]. Briefly, the first step leading to small intestinal mucosal injury is considered to be the topical toxicity of NSAIDs, which induces the uncoupling of mitochondrial oxidative phosphorylation in epithelial cells.…”

The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication

“…They state that PPIs are dangerous medications and, among their potential adverse events on many body organs, as recently reported in medical literature with added hyperbole, the frequent damage of the small bowel cannot be dismissed [2]. So, the beneficial use of PPIs in healing and preventing the formation of NSAID-induced gastric ulcers, largely documented in many clinical trials and meta-analyses [3-5], can be associated with the increase of NSAID enteropathy, which seems to be due to gram-negative intestinal dysbiosis [6]. The above Authors conclude that PPIs should not be administered to reduce the harm of NSAIDs on gastric mucosa and should be replaced by other agents, such as rebamipide, which has been shown to protect the whole gastroenteric mucosa [1].…”

Foxo3a aggravates inflammation and induces apoptosis in IL-1-treated rabbit chondrocytes via positively regulating tenascin-c

“…2020 10.5603/FHC.a2019.0022 www.journals.viamedica.pl/folia_histochemica_cytobiologica chondrocytes, as well as mitochondrial dysfunction, metabolic disorders and other abnormal molecular signals are involved in the massive loss of cartilage, which are characteristics of OA [5]. Non-steroidal anti-inflammatory drugs (NSAIDs), the most common clinical treatment for OA, cause several serious side effects like peptic ulcer, nervous system dysfunction and bleeding after long-term use [6].…”